equipped for crypto

Houston startup that simplifies way to analyze cryptocurrency trends plans expansion

Cryptocurrency doesn't have to be a big, confusing risk with this Houston startup's technology. David McBee/Pexels

A new Houston startup is changing the way traders and investors analyze trending cryptocurrency.

Spencer Randall, CryptoEQ's principal and co-founder, says the mission of the company is to simplify ratings and analysis in cryptocurrency. With the company's beta now live, Randall hopes that those not familiar with cryptocurrency will be able to use the platform as a learning tool. The platform takes information on trending cryptocurrency and boils it down into three columns -- rating, technical analysis and trend analysis -- in order for users to know when to buy or sell.

"(It) is very complex," Randall says. "We see the utility and digital assets helping the common person so that they can try and boil down the information."

Randall, whose interest in investing and trading in cryptocurrency began a couple of years ago, became a frequent attendee of Bitcoin meetups in Houston, Austin, and San Antonio. There, he met his co-founders, lead designer Brooks Vaughan, program manager Norman Hamilton, lead analyst Michael Thoma, and lead marketer Joseph Romero.

The co-founders all recognized a need for reliable and trustworthy information in the cryptocurrency space and decided that creating CryptoEQ was the answer. The company hopes to expand its platform by the end of the third quarter this year.

"We really wanted to start building a platform that we would want to use as people organically enthusiastic about the (cryptocurrency) space," Randall says. "We built the platform for use at those meetups. It has a landing page where you can just jump on and get a feel in a matter of seconds of how the market is doing. This beta is intended to be a place where you can come throughout the day to check in on the market and check in on how things are going and learn about where'd you like to go next with crypto."

And while Houston is still an expanding technology hub, Randall thinks the city is an undervalued place to grow a small company like CryptoEQ. He credits innovation hubs like the Rice University's Liu Idea Lab for Innovation and Entrepreneurship, also known as Lilie, for creating the opportunity for Houstonians to thrive in the startup field.

"Houston is a place where entrepreneurs can actually thrive," Randall said. "You see a lot of people go to Austin because that's where the startup culture is in Texas. As Houston catches up, I think you'll see less of the talent leave."

CryptoEQ offices out of The Cannon, which is opening its 120,000-square-foot entrepreneurial campus this summer.


The CryptoEQ founders met at various Texas Bitcoin meetups. Courtesy of CryptoEQ

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted